## GUIDELINE

# Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline

Zhikang Ye PhD, Bram Rochwerg MD MSc, Ying Wang MPharm, Neill K. Adhikari MD, Srinivas Murthy MD, François Lamontagne MD, Robert A. Fowler MD, Haibo Qiu MD, Li Wei B Pharm, Ling Sang MD, Mark Loeb MD MSc, Ning Shen MD, Minhua Huang, Zhaonan Jiang, Yaseen M. Arabi MD, Luis Enrique Colunga-Lozano MD MSc, Li Jiang MD, Younsuck Koh MD, Dong Liu PhD, Fang Liu MSc, Jason Phua MRCP, Aizong Shen MSc, Tianyi Huo BSc, Bin Du MD, Suodi Zhai BSc, Gordon H. Guyatt MD MSc

O n Mar. 11, 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic. The worldwide spread of COVID-19 represents a profound threat to human health.

Patients with COVID-19 present primarily with fever, cough, and myalgia or fatigue, and sometimes initially with predominantly gastrointestinal symptoms. A minority of patients progress to severe pneumonia, and about 15% of these patients to critical illness characterized by acute respiratory distress syndrome (ARDS), which is associated with mortality of about 50%.[1–3]

The enormity of the adverse health consequences of COVID-19 has understandably left clinicians and patients eager for interventions that can decrease progression, prevent mortality and speed recovery. This eagerness has perhaps contributed to overly sanguine assessments from experts, regulatory authorities and prominent politicians regarding the potential benefits of treatments, with underappreciation of potential harms.[4,5]

Use of medication without established effectiveness can undermine public trust, result in unnecessary harm, compromise investigations that might provide definitive answers and divert resources from truly beneficial interventions. Evidence-based guidelines for treatment of patients with COVID-19 provide one strategy for avoiding overuse of highly touted but unestablished therapies.

Therefore, we have developed an evidence-based guideline that focuses on both patients with nonsevere and severe COVID-19 and, for use of corticosteroids, patients with ARDS. Our guideline process followed standards of trustworthy guidelines,[6]

## KEY POINTS

- The available evidence for treatment of coronavirus disease 2019 (COVID-19) is either indirect (from studies of influenza, severe acute respiratory syndrome and Middle East respiratory syndrome) or from several observational studies and randomized controlled trials in patients with COVID-19, which are limited in sample size and rigour, permitting only weak recommendations.

- Given the inevitable adverse effects of interventions, the guideline panel (which included 2 patient partners) inferred that most informed patients would decline treatment when only very low-quality evidence of benefits — and, thus, very large uncertainty — is available.

- The panel made only 1 weak recommendation in favour of treatment: use of corticosteroids in patients with acute respiratory distress syndrome (ARDS), based on indirect evidence.

- The panel made weak recommendations against use of corticosteroids in patients without ARDS, against use of convalescent plasma and against several antiviral drugs that have been suggested as potential treatments for COVID-19.

- Rigorous randomized trials are urgently needed to establish the benefits and risk of candidate interventions.

including use of widely adopted Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology for rating quality of evidence and grading strength of recommendations.[7] Given the anticipated paucity of evidence from studies enrolling patients with COVID-19, the recommendations hinge on both direct and relevant indirect evidence.

## Scope

Health care providers represent the target audience of this guideline. The guideline includes 3 categories of interventions: corticosteroids, convalescent plasma therapy and antiviral drugs. We address the use of these interventions for COVID-19 in patients with nonsevere disease, severe disease and, for corticosteroids, those with ARDS, as the balance of benefits may differ among these groups. For instance, the death rate in patients with nonsevere COVID-19 is estimated to be 1/1000 and in those with severe disease is estimated at more than 100/1000, thus providing much more scope for important benefit in severe COVID-19.[1]

Our definition of severe COVID-19 pneumonia follows that of the WHO: fever or suspected respiratory infection, plus 1 of the following: respiratory rate > 30 breaths/min, severe respiratory distress, or arterial oxygen saturation measured by pulse oximeter ($SpO_2$) ≤ 93% on room air.[8] The WHO definition of "severe" includes patients admitted to hospital with pneumonia who can be managed on medical wards and are not critically ill. Best evidence suggests that about 85% of such patients will never progress to critical illness such as ARDS.[1]

Because we anticipate that clinicians are unlikely to consider the use of convalescent plasma in patients with nonsevere COVID-19, for this intervention we addressed only patients with severe COVID-19. Similarly, clinicians are unlikely to consider corticosteroids in patients with nonsevere infection; in addressing corticosteroids use, we therefore focused on patients with severe COVID-19 and those with ARDS.

## Recommendations

Box 1 summarizes the recommendations. We made 1 weak recommendation in favour of a treatment (corticosteroids in severe COVID-19 with ARDS) and made weak recommendations against use of the other treatments included in this guideline.

---

**Box 1: Summary of recommendations**

*We suggest using corticosteroids in patients with severe coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (weak recommendation).*

- The agent, dose and duration of corticosteroid varied in the relevant randomized controlled trials. Methylprednisolone 40 mg intravenously for 10 days represents 1 reasonable regimen used by critical care clinicians on our panel.

*We suggest not using corticosteroids in patients with severe COVID-19 who do not have ARDS (weak recommendation).*

- If clinicians choose to use corticosteroids in patients who do not have ARDS, lower doses of corticosteroids for short periods may reduce the likelihood of toxicity.

*We suggest not using convalescent plasma in patients with severe COVID-19 (weak recommendation).*

*We suggest not using ribavirin, umifenovir, favipiravir, lopinavir-ritonavir, hydroxychloroquine, interferon-α and interferon-β in patients with nonsevere COVID-19 (weak recommendation).*

*We suggest not using ribavirin, umifenovir, favipiravir, lopinavir-ritonavir, hydroxychloroquine, interferon-α and interferon-β in patients with severe COVID-19 (weak recommendation).*

---

## Corticosteroids

*We suggest using corticosteroids in patients with severe COVID-19 and ARDS (weak recommendation).*

*Comment: The agent, dose and duration of corticosteroid varied in the relevant randomized controlled trials (RCTs). Methylprednisolone 40 mg intravenously for 10 days represents 1 reasonable regimen used by critical care clinicians on our panel.*

### Direct evidence

In 1 observational study[3] of patients with severe COVID-19 and ARDS, the administration of methylprednisolone reduced the risk of death (adjusted hazard ratio [HR] 0.41, 95% confidence interval [CI] 0.20 to 0.83; very low-quality evidence) (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.200648/-/DC1).[9]

### Indirect evidence

The biological rationale for administering corticosteroids in a variety of conditions causing ARDS — including viral infections, bacterial infections and noninfectious causes — is similar and relates to the effect of corticosteroids on the inflammatory cascade and subsequent alveolitis leading to respiratory compromise. Evidence from 851 patients with ARDS in 7 RCTs suggests that use of corticosteroids results in a reduction in mortality that, applied to patients with COVID-19, may reduce deaths by 17.3% (95% CI –27.8% to –4.3%; low-quality evidence) (Appendix 1).[9]

Corticosteroids may reduce the duration of mechanical ventilation by more than 4 days (low-quality evidence), but we are very uncertain regarding the effect of corticosteroids on length of stay in the intensive care unit (ICU) and length of hospital stay (Appendix 1).[9]

Corticosteroids may increase serious hyperglycemia events by 8.1% (low-quality evidence), may have little or no effect on gastrointestinal bleeding and neuromuscular weakness (low-quality evidence), and probably have little or no effect on super-infection (moderate-quality evidence) (Appendix 1).[9]

### Rationale

Use of corticosteroids in patients with severe COVID-19 and ARDS may result in a substantial reduction in mortality, a critical outcome. The harm of short-term use of corticosteroids is limited. Based on our inferences regarding patients' values and preferences, we made a weak recommendation in favour of corticosteroids.

*We suggest not using corticosteroids in patients with severe COVID-19 who do not have ARDS (weak recommendation).*

*Comment: If clinicians choose to use corticosteroids in patients who do not have ARDS, lower doses of corticosteroids for short periods may reduce the likelihood of toxicity.*

### Direct evidence

Very low-quality evidence from 2 cohort studies[10,11] that included 331 patients with severe COVID-19 raised the possibility that corticosteroids may increase mortality compared with no corticosteroids (HR 2.30, 95% CI 1.00 to 5.29); 1 of these studies[11] is a preprint (Appendix 1).[9]

### Indirect evidence

Very low-quality evidence from 6129 patients with severe acute respiratory syndrome (SARS) in 2 observational studies[12,13] raises the possibility that corticosteroids may reduce mortality. Evidence from 290 patients with Middle East respiratory syndrome (MERS) in 1 observational study[14] also suggests that corticosteroids may reduce mortality, but again the evidence is very low quality. Evidence from SARS and MERS provides very low-quality evidence that corticosteroids may delay clearance of coronavirus ribonucleic acid (RNA) (Appendix 1).[9] Efforts should be made to study corticosteroids for viral pneumonia (as distinct from ARDS) in RCTs.

Very low-quality evidence from 8530 patients with influenza in 11 observational studies raises the possibility that corticosteroids may increase mortality. It remains possible that corticosteroids increase superinfection and the need for mechanical ventilation (very low-quality evidence) (Appendix 1).[9]

Very low-quality evidence from 2034 patients with community-acquired pneumonia in 13 RCTs raises the possibility that corticosteroids may reduce mortality. Corticosteroids may reduce the need for mechanical ventilation by 10.4% (95% CI –13.8% to –4.3%; low-quality evidence), while very low-quality evidence raises the possibility of reductions in length of ICU stay, length of hospital stay and duration of mechanical ventilation. Corticosteroids probably increase serious hyperglycemia events by 8.4% (95% CI 5.2% to 12.4%; moderate-quality evidence) and may increase neuropsychiatric events and superinfection events (low-quality evidence). Corticosteroids may have little or no effect on gastrointestinal bleeding (low-quality evidence) (Appendix 1).[9]

### Rationale

In patients with severe COVID-19 outside the ICU, any benefit of corticosteroids is less than in those with ARDS. The indirect evidence regarding mortality was very low quality and inconsistent among SARS, MERS, influenza and community-acquired pneumonia. Low- and moderate-quality evidence suggests that corticosteroids, when used over the short term, have modest harm. In this context, when any benefit is very uncertain, our inferences regarding patient values and preferences dictate a weak recommendation against use of corticosteroids in patients with severe COVID-19 who do not have ARDS.

### Convalescent plasma

*We suggest not using convalescent plasma in patients with severe COVID-19 (weak recommendation).*

### Indirect evidence

Very low-quality evidence from 40 patients with SARS in 1 observational study[15] raises the possibility that convalescent plasma may reduce mortality (Appendix 2, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.200648/-/DC1).[16]

Four RCTs[17–20] that included 572 patients with influenza contributed to very low-quality evidence suggesting that convalescent plasma may have little to no effect on mortality, may have a small benefit in hastening recovery and may reduce length of hospital stay and duration of mechanical ventilation. Use of convalescent plasma may result in little or no difference in rate of serious adverse events (–1.2%, 95% CI –3.5% to 2.3%; low-quality evidence) (Appendix 2).[16]

### Rationale

Very low-quality evidence raised the possibility that convalescent plasma may have some benefit in important outcomes and may be safe. Given the resources associated with preparation and administration of convalescent plasma, we have insufficient evidence to support its use.

### Antiviral drugs

*We suggest not using ribavirin, umifenovir (Arbidol), favipiravir, lopinavir-ritonavir, hydroxychloroquine, interferon-α and interferon-β in patients with nonsevere COVID-19 (weak recommendation).*

Because the likelihood of death from COVID-19 in patients with nonsevere disease is extremely low (in the range of 1/1000), we are very confident that antiviral drugs will have little or no effect on mortality in such patients.[1]

An RCT[21] of umifenovir and lopinavir-ritonavir reported other relevant outcomes in patients with nonsevere COVID-19, including cough, fever and progression to severe disease, but the RCT included only a total of 23 patients treated with umifenovir and 28 patients treated with lopinavir-ritonavir; as a result, the confidence intervals were so wide as to make the evidence uninformative (Appendix 3, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.200648/-/DC1).[22] One observational study[23] in 120 patients with COVID-19 with mixed-severity disease provides very low-quality evidence that lopinavir-ritonavir may increase viral clearance at day 23 (Appendix 3).[22]

With respect to interferon-α, an observational study[24] in 70 patients with mixed-severity COVID-19 provides very low-quality evidence that the addition of interferon-α to umifenovir therapy may not affect time to viral clearance or length of hospital stay relative to umifenovir alone. There is no published evidence regarding benefit or harm of interferon-β or ribavirin in patients with nonsevere COVID-19.

With regard to favipiravir, an RCT[25] in 236 patients with mixed-severity COVID-19 suggested, in comparison with umifenovir, a possible higher incidence of recovery at day 7, but because of risk of bias, imprecision and indirectness, the evidence was only very low quality (Appendix 3).[22] One observational study[26] in 80 patients with nonsevere COVID-19 provides very low-quality evidence that favipiravir may increase viral clearance at day 7 relative to lopinavir-ritonavir. Symptomatic benefit outcomes from patients with nonsevere disease for other agents were unavailable.

Turning to harms, studies of interferon-α did not address symptomatic harms. Observational studies suggested substantial increases in anemia (26%) and bradycardia (15%) with ribavirin, but whether patients experienced symptoms remains uncertain.[27] Evidence regarding adverse effects in umifenovir is very low quality, and for favipiravir is low quality (Appendix 3).[22] An RCT[28] of lopinavir-ritonavir provides moderate-quality evidence of increased diarrhea (6%), nausea (9.5%) and vomiting (6.3%) with this drug combination.

Evidence for hydroxychloroquine came from 3 RCTs[29–31] of 240 patients with nonsevere COVID-19. Because of serious risk of bias (lack of blinding), imprecision (wide confidence intervals) and indirectness (both intervention and control groups included other drugs, limiting inferences regarding the effect of hydroxychloroquine), these studies provided very low-quality evidence

regarding the following possible effects: little or no effect on viral clearance, a small reduction in duration of fever, little or no progression from nonsevere to severe disease, and little or no effect on recovery at day 7 (Appendix 3).[22] Hydroxychloroquine may cause diarrhea in about 10% of patients (low-quality evidence). Very low-quality evidence suggests possible increases in headache, rash, nausea, vomiting and blurred vision (Appendix 3).[22]

### Rationale

Because of a very low incidence of death, antiviral drugs cannot result in important mortality reductions in patients with nonsevere disease. We have no persuasive evidence of symptomatic benefit for any drug, with evidence of appreciable harm with ribavirin and lopinavir-ritonavir and high uncertainty regarding adverse effects in other drugs. Efforts should be made to study these agents in RCTs.

For all drugs to this point, the panel reached a consensus. For hydroxychloroquine, there was no suggestion of benefit in patients with nonsevere COVID-19, with possible increases in rash, nausea and vomiting. For hydroxychloroquine, 15 panel members voted for a weak recommendation against the drug, 3 voted for no recommendation, and 7 members had intellectual competing interests and did not vote.

*We suggest not using ribavirin, umifenovir, favipiravir, lopinavir-ritonavir, hydroxychloroquine, interferon-α and interferon-β in patients with severe COVID-19 (weak recommendation).*

### Indirect evidence

Observational studies[12,32–34] of ribavirin and interferon in non–COVID-19 coronaviruses (SARS and MERS) provide point estimates suggesting mortality reductions, but confidence intervals are very wide and include mortality increases; overall, the evidence is very low quality (Appendix 3).[22] As presented in the previous section, an observational study[27] suggests frequent anemia and bradycardia in patients receiving ribavirin, but the effect on patient experience remains uncertain.

### Direct evidence

We have no direct evidence for ribavirin or interferon-β in severe COVID-19 disease. For interferon-α, as presented in the previous section, an observational study[24] provides very low-quality evidence that the drug has minimal or no effect on time to viral clearance or length of hospital stay.

For umifenovir, the only RCT[21] enrolled 23 patients with nonsevere COVID-19 disease, leaving (in addition to indirectness of evidence from patients with nonsevere disease) confidence intervals for all outcomes so wide as to be uninformative (Appendix 3).[22] An observational study[35] in 504 patients with mixed-severity COVID-19 provides very low-quality evidence that umifenovir may decrease mortality.

For favipiravir, we noted in the previous section the very low-quality evidence of increased viral clearance relative to lopinavir-ritonavir (Appendix 3). An RCT[36] of lopinavir-ritonavir in 386 patients with influenza suggests the drug may not cause diarrhea (the results of this RCT have not yet been published).

Evidence from 199 patients with severe COVID-19 in 1 RCT[28] suggests that lopinavir-ritonavir may reduce mortality by 2.4%

(95% CI –5.7% to 3.1%), length of ICU stay by 5 days (95% CI –9 to 0), and length of hospital stay by 1 day (95% CI –2 to 0), but given the 95% confidence intervals, the results include the possibility of no effect (all low-quality evidence, from imprecision and risk of bias). We found moderate-quality evidence of increases in diarrhea (6%), nausea (9.5%) and vomiting (6.3%) for lopinavir-ritonavir (Appendix 3).[22] As presented in the previous section, 1 observational study[23] in 120 patients with mixed-severity COVID-19 provides very low-quality evidence that lopinavir-ritonavir may increase viral clearance at day 23 (Appendix 3).[22] Very low-quality evidence from 181 patients with severe COVID-19 and 255 patients with mixed-severity disease in 2 observational studies (preprints)[37,38] raised the possibility that hydroxychloroquine may increase mortality and the need for mechanical ventilation (Appendix 3).[22]

### Rationale

Very low-quality evidence raised the possibility that ribavirin, umifenovir, favipiravir, interferon-α and interferon-β may have little or no benefit in mortality for patients with severe COVID-19. We are also very uncertain regarding the safety of these drugs in patients with severe disease.

The panel reached consensus on all recommendations regarding antiviral drugs mentioned thus far. As described above, however, for lopinavir-ritonavir, although 1 RCT[28] suggested the combination may reduce mortality, the 95% CI (–5.7% to 3.1%) included a 3.1% increase in mortality, and because of an open-label design, the study was at high risk of bias. Similarly, the 95% CI with respect to estimates of decreased length of ICU and hospital stay included no effect, and the evidence was overall low quality. Considering the uncertainty and the likely increases in diarrhea (best estimate 6%), nausea (9.0%) and vomiting (6.4%), the panel made a weak recommendation against the use of lopinavir-ritonavir. Ultimately, 14 panel members voted to recommend against the drug combination, and 6 were in favour; 5 members had intellectual competing interests and did not vote.

In patients with severe COVID-19, 2 observational studies[37,38] raised the possibility that hydroxychloroquine may increase mortality and the need for mechanical ventilation. Ultimately, 15 panel members voted for a weak recommendation against the drug, 3 voted for no recommendation, and 7 members had intellectual competing interests and did not vote.

## Methods

### Group composition and process

The guideline steering committee comprised 5 members: the guideline chair (G.G.), the project lead (Z.Y.), a COVID-19 clinical investigator and clinical expert (B.D.), an academic pharmacist investigator (S.Z.) and a critical care physician and methodologist (B.R.). The main roles of the guideline steering committee included defining the scope of the guideline; proposing the initial specific clinical questions addressed by this guideline; choosing guideline panel members, including reviewing competing interests; determining the rules for reaching consensus or voting; overseeing the process of developing all affiliated systematic reviews and the summary of findings tables, and ensuring deadlines were met; and pro-

posing the initial values and preferences that the panel ultimately endorsed for use in this guideline.

The guideline panel comprised 26 members from 6 countries (China, Canada, South Korea, Saudi Arabia, Singapore, Mexico) and included 6 critical care physicians, 5 pharmacists, 3 respiratory physicians, 1 infectious diseases physician, 1 nurse, 1 patient partner who had recovered from mild and 1 from severe COVID-19, and 8 methodologists, all of whom are also involved in clinical care (Appendix 4, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.200648/-/DC1, contains the full list of guideline panel members).

The guideline panel met 3 times by videoconference (Feb. 28, Mar. 23, and Mar. 24, 2020). Before the first meeting and between the first and second panel meetings, the steering committee also met to discuss issues of scope, population and approaches to summarizing indirect evidence, planning the systematic reviews and formulating recommendations.

Following these meetings, the panel continued with email correspondence; in particular, the panel reviewed a revised summary of findings table on hydroxychloroquine after our identification of new evidence in April 2020 and revoted on the corresponding recommendation on Apr. 25, 2020.

### Selection of priority questions

At its first meeting, the guideline panel established the issues to be addressed in the guideline, based on the members' judgment of the questions of foremost concern to clinicians treating patients with nonsevere and severe COVID-19. The earlier section on "Scope" outlines the populations and interventions on which the panel chose to focus. The panel advised the systematic review teams on the priority outcomes of interest.

### Summarizing the evidence

Following recommended methods,[39] an independent group of systematic reviewers, with direction from the guideline steering committee and input from the panel, conducted 3 systematic reviews of the evidence relevant to our questions.[9,16,22] The reports of these 3 systematic reviews (1 addressing corticosteroids, 1 on antiviral agents and 1 on convalescent plasma) included searches on MEDLINE, Embase, PubMed, Cochrane Central Register of Controlled Trials and medRxiv in March 2020 and applied no restriction on the language of publication. Additional details regarding the searches are available in the systematic reviews.[9,16,22] We included RCTs, cohort and case–control studies, but not single-arm studies. We also updated the direct evidence from COVID-19 to Apr. 25, 2020.

To assess risk of bias in RCTs, we used a modified version of the Cochrane 1.0 risk of bias instrument.[40] To assess risk of bias in cohort and case–control studies, we used instruments developed by the CLARITY (Clinical Advances through Research and Information Translation) research group at McMaster University, Hamilton, Ontario.[41,42]

Using the GRADE approach, bodies of evidence were rated as high, moderate, low or very low quality. Randomized controlled trials began as high quality and observational studies as low quality.[43] Issues of risk of bias,[44] imprecision,[45] inconsistency,[46] indirectness[47] and publication bias[48] could lead to rating down of the quality of the study. The presence of a large magnitude of association or a dose–response gradient could lead to rating up of the quality of an observational study.[49]

We summarized evidence in GRADE summary of findings tables, presenting both relative and absolute effects. We obtained absolute effects by applying estimates of relative effects, sometimes from non–COVID-19 populations, to baseline risks that came from COVID-19 populations. In this document, because these are of most importance to patients, we present only absolute effects.

Because we anticipated a paucity of direct evidence from studies of patients with COVID-19, we summarized related indirect evidence from patients with SARS, MERS, ARDS, influenza, community-acquired pneumonia and, for adverse effects of convalescent plasma, Ebola virus disease. Using the GRADE approach, for efficacy outcomes from patients with SARS or MERS, we rated the evidence down 1 category for indirectness; for efficacy evidence from ARDS, influenza, community-acquired pneumonia and other acute viral infectious diseases, we rated the evidence down 2 categories for very indirect evidence. The panel considered evidence regarding adverse effects as less indirect than efficacy evidence and so rated the evidence down only once, or in some cases not at all, for indirect evidence.

### Values and preferences

On the basis of the panel members' experience with patients, input from the 2 patient partners on the panel and knowledge of the limited available evidence, the panel specified the following value and preference judgments that were used to inform the recommendations. First, when modest harms were present and there was low-quality evidence of a small but important difference in an outcome important to patients (e.g., mortality), most patients would choose to receive an intervention. That is, most patients would place a higher value on an uncertain, small but important benefit than in avoiding modest harms. Second, when low-quality evidence suggests little or no benefit, or when only very low-quality evidence exists and effects are therefore very uncertain, most patients would decline the intervention.

### Formulation of recommendations

The guideline panel developed the recommendations during the second and third guideline panel meetings and, as mentioned previously, for hydroxychloroquine during subsequent email correspondence. The panel had access to the summary of findings tables before the meetings, and the chair reviewed the details of the tables at the meetings. The recommendations were formulated at the meetings, after review of the evidence, based on magnitude of benefits and harms, quality of supporting evidence, and underlying values and preferences with, when relevant, some consideration of resource expenditure (Box 2).

The aim of the panel discussion was first to achieve consensus, which was successful for most recommendations. If the panel did not achieve consensus, a formal vote occurred, requiring 70% in favour of 1 option to make a recommendation. If the 70% threshold was not achieved, our process was to declare the panel undecided, make no recommendation, and instead report the vote and associated rationale. The chair endeavoured to guide the panel toward consensus without taking a position, and did not participate in the voting.

## Management of competing interests

Our competing interest procedures adhered to Guidelines International Network principles.[50] We collected both direct (financial) and indirect (intellectual) disclosures for all participants at the start of the guideline process and before publication. We excluded from the panel individuals with personal financial competing interests. Panel members completed a declaration of competing interests that steering committee members considered in making final decisions regarding conflicts, on a recommendation-by-recommendation basis (Appendix 5, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.200648/-/DC1). Members with intellectual conflicts, which included ongoing research addressing the treatments being considered, were permitted to participate in discussion but not in making decisions regarding recommendations for which they had competing interests.

| Table 1 (part 1 of 2): International recommendations on the treatment of COVID-19 | | | | | | |
|---|---|---|---|---|---|---|
| **Intervention** | **IDSA guideline (Apr. 21, 2020)[51]** | **SSC guideline (Mar. 23, 2020)[52]** | **WHO interim guidance (Mar. 13, 2020)[8]** | **ANZICS guideline (version 1, Mar. 16, 2020)[53]** | **NICE guideline (Apr. 3, 2020)[54]** | **This guideline** |
| **Corticosteroids\*** | Among patients who have been admitted to hospital with COVID-19 pneumonia, the IDSA guideline panel suggests against the use of corticosteroids (conditional recommendation, very low-certainty evidence). | In adults on mechanical ventilation with COVID-19 and respiratory failure (without ARDS), the SSC guideline suggests against the routine use of systemic corticosteroids (weak recommendation). | The WHO interim guidance recommends not routinely giving systemic corticosteroids for treatment of viral pneumonia outside clinical trials. | The ANZICS guideline does not recommend corticosteroids for routine use in acute respiratory failure with COVID-19. Some patients will have appropriate alternative clinical indications for the use of corticosteroids, such as the presence of septic shock. | The NICE guideline recommends not routinely offering a corticosteroid unless the patient has other conditions for which these are indicated, such as asthma or chronic obstructive pulmonary disease. | We suggest using corticosteroids in patients with severe COVID-19 and ARDS (weak recommendation). |
| | Among patients who have been admitted to hospital with ARDS owing to COVID-19, the IDSA guideline panel recommends the use of corticosteroids in the context of a clinical trial (knowledge gap). | In adults on mechanical ventilation with COVID-19 and ARDS, the SSC guideline suggests using systemic corticosteroids, over not using corticosteroids (weak recommendation). | | | | We suggest not using corticosteroids in patients with severe COVID-19 who do not have ARDS (weak recommendation). |
| **Convalescent plasma\*** | Among patients who have been admitted to hospital with COVID-19, the IDSA guideline panel recommends COVID-19 convalescent plasma in the context of a clinical trial (knowledge gap). | In adults who are critically ill with COVID-19, the SSC guideline suggests against the routine use of convalescent plasma (weak recommendation). | NR | NR | NR | We suggest not using convalescent plasma in patients with severe COVID-19 (weak recommendation). |

## Table 1 (part 2 of 2): International recommendations on the treatment of COVID-19

| Intervention | IDSA guideline (Apr. 21, 2020)[51] | SSC guideline (Mar. 23, 2020)[52] | WHO interim guidance (Mar. 13, 2020)[8] | ANZICS guideline (version 1, Mar. 16, 2020)[53] | NICE guideline (Apr. 3, 2020)[54] | This guideline |
|---|---|---|---|---|---|---|
| **Antiviral drugs** | | | | | | |
| Umifenovir | NR | NR | NR | NR | NR | We suggest not using umifenovir in patients with nonsevere and severe COVID-19 (weak recommendation). |
| Favipiravir | NR | NR | NR | NR | NR | We suggest not using favipiravir in patients with nonsevere and severe COVID-19 (weak recommendation). |
| Hydroxychloroquine | Among patients who have been admitted to hospital with COVID-19, the IDSA guideline panel recommends hydroxychloroquine in the context of a clinical trial (knowledge gap). | Insufficient evidence to make a recommendation | NR | NR | NR | We suggest not using hydroxychloroquine in patients with nonsevere and severe COVID-19 (weak recommendation). |
| Interferon-α | NR | NR | NR | NR | NR | We suggest not using interferon-α in patients with nonsevere and severe COVID-19 (weak recommendation). |
| Interferon-β | NR | NR | NR | NR | NR | We suggest not using interferon-β in patients with nonsevere and severe COVID-19 (weak recommendation). |
| Lopinavir-ritonavir | Among patients who have been admitted to hospital with COVID-19, the IDSA guideline panel recommends the combination of lopinavir-ritonavir only in the context of a clinical trial (knowledge gap). | In critically ill adults with COVID-19, the SSC guideline suggests against the routine use of lopinavir-ritonavir (weak recommendation). | NR | NR | NR | We suggest not using lopinavir-ritonavir in patients with nonsevere and severe COVID-19 (weak recommendation). |
| Ribavirin | NR | NR | NR | NR | NR | We suggest not using ribavirin in patients with nonsevere and severe COVID-19 (weak recommendation). |

Note: ANZICS = Australian and New Zealand Intensive Care Society, ARDS = acute respiratory distress syndrome, COVID-19 = coronavirus disease 2019, IDSA = Infectious Diseases Society of America, NICE = National Institute for Health and Care Excellence, NR = not reported, SSC = Surviving Sepsis Campaign, WHO = World Health Organization.
*These interventions were not considered for use in patients with nonsevere COVID-19 in this guideline.

## Implementation

This guideline will be available in user-friendly and multilayered formats for clinicians and patients through MAGICapp (https://app.magicapp.org/app#/guideline/EK6W0n). This will include interactive GRADE summary of findings tables and consultation decision aids to facilitate shared decision-making. The guideline will be updated on MAGICapp as new information becomes available.

Additionally, the participants in this guideline anticipate being part of a wider effort to produce new recommendations rapidly when higher-quality practice-confirming or practice-changing evidence from RCTs becomes available.

The recommendations in this guideline should discourage use of interventions for which there is very low-quality evidence, thus decreasing medical waste. However, misleading statements about and advocacy for use of medications for which we were unable to find robust evidence of benefit at this time present the major barriers to this guideline's implementation.

## Other guidelines

Table 1 summarizes the recommendations addressing corticosteroids, convalescent plasma and antiviral drugs from 5 guidelines on COVID-19, from the Infectious Diseases Society of America (IDSA),[51] Surviving Sepsis Campaign (SSC),[52] WHO,[8] Australian and New Zealand Intensive Care Society (ANZICS)[53] and UK National Institute for Health and Care Excellence (NICE).[54]

With respect to corticosteroids and ARDS, IDSA recommends use only in the clinical trial context; SSC suggests in favour; and WHO, ANZICS and NICE all recommend against. In patients without ARDS, all guidelines recommend against use of corticosteroids.

Regarding convalescent plasma, IDSA recommends its use only in the context of a clinical trial. The SSC and our guideline suggested not using convalescent plasma. Other guidelines did not address convalescent plasma.

The IDSA recommended use of lopinavir-ritonavir only in the context of a clinical trial, and SSC, like our guideline, suggested against using this drug. The other guidelines did not address lopinavir-ritonavir. The IDSA recommended use of hydroxychloroquine only in the context of a clinical trial, and SSC made no recommendation on hydroxychloroquine; the other guidelines did not address hydroxychloroquine. None of these guidelines addressed any of the other drugs for which our guideline made recommendations.

## Gaps in knowledge

The benefits and, to a considerable extent, the harms, associated with the interventions addressed in this guideline remain very uncertain. Although RCT evidence is required for all agents considered, the more promising agents should likely receive higher priority.

Because of the most promising evidence of important benefits at present, we suggest conduct of large, methodologically sophisticated RCTs to address the effect of corticosteroids in patients with severe COVID-19 and particularly those with ARDS, and lopinavir-ritonavir and umifenovir in severe COVID-19. Hydroxychloroquine would be another candidate for further study, not because of current evidentiary support from human studies, but rather because of the results from preclinical studies and the attention the drug has received thus far.

A large number of RCTs are under way to assess interventions in COVID-19, including an important WHO-sponsored initiative, the SOLIDARITY trial.[55]

## Limitations

At the time we determined the scope of the guideline, we decided not to include remdesivir because it was not licensed for use anywhere in the world and tocilizumab because there were no studies available regarding its use. Both drugs are now among those being considered for use in COVID-19 and our failure to address them constitutes a limitation of this guideline.

The composition of the guideline panel represents another limitation: our panel included more men than women, and panellists were mainly from China and Canada.

## Conclusion

Given the largely very low-quality evidence regarding benefits of the treatments that the panel considered, and given the panel's inferences regarding patient values and preferences, the panel made almost exclusively weak recommendations against use of the interventions included in this guideline. The research community should interpret the weak recommendations that this guideline offers as a call to urgently undertake rigorous RCTs of the candidate interventions.

## References

1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. *N Engl J Med* 2020 Feb. 28 [Epub ahead of print]. doi: 10.1056/NEJMoa2002032.

2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.

3. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020 Mar. 13 [Epub ahead of print]. doi: 10.1001/jamainternmed.2020.0994.

4. Coehn E, Bonifield J, Nigam M. Trump says this drug has "tremendous promise," but Fauci's not spending money on it. *CNN* 2020 Apr. 10. Available: www.cnn.com/2020/03/28/health/coronavirus-hydroxychloroquine-trial/index.html (accessed 2020 Apr. 26).

5. Kalil AC. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. *JAMA* 2020 Mar. 24 [Epub ahead of print]. doi: 10.1001/jama.2020.4742.

6. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines; Graham R, Mancher M, Miller Wolman D, et al, editors. *Clinical practice guidelines we can trust*. Washington (D.C.): National Academy of Sciences; 2011.

7. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-6.

8. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. Geneva: World Health Organization; 2020 Mar. 13.

9. Ye Z, Wang Y, Colunga-Lozano L, et al. Efficacy and safety of corticosteroids in COVID-19: a systematic review and meta-analysis including summaries of indirect evidence from ARDS, SARS, MERS, influenza, and community acquired pneumonia. *CMAJ* 2020. In press.

10. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020 Apr. 12 [Epub ahead of print]. doi: 10.1016/j.jaci.2020.04.006. .

11. Lu X, Chen T, Wang Y, et al. Adjuvant corticosteroid therapy for critically ill patients with COVID-19. *MedRxiv* 2020 Apr. 7. doi: 10.1101/2020.04.07.20056390.

12. Lau EHY, Cowling BJ, Muller MP, et al. Effectiveness of ribavirin and corticosteroids for severe acute respiratory syndrome. *Am J Med* 2009;122:1150.e11-21.

13. Long Y, Xu Y, Wang B, et al. Clinical recommendations from an observational study on MERS: glucocorticoids was benefit in treating SARS patients. *Int J Clin Exp Med* 2016;9:8865-73.

14. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. *Am J Respir Crit Care Med* 2018;197:757-67.

15. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clin Microbiol Infect* 2004;10:676-8.

16. Devasenapathy N, Ye Z, Loeb M, et al. Indirect evidence on efficacy and safety of convalescent plasma in severe COVID-19 patients: systematic review and meta-analysis. *CMAJ* 2020. In press.

17. Beigel JH, Aga E, Elie-Turenne MC, et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. *Lancet Respir Med* 2019;7:941-50.

18. Beigel JH, Tebas P, Elie-Turenne MC, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. *Lancet Respir Med* 2017;5:500-11.

19. Davey RT, Fernandez-Cruz E, Markowitz N, et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. *Lancet Respir Med* 2019;7:951-63.

20. Hung IFN, To KKW, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. *Chest* 2013;144:464-73.

21. Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). *medRxiv* 2020 Apr. 15. doi: 10.110/2020.03.19.20038984.

22. Liu W, Zhou P, Chen K, et al. Efficacy and safety of antiviral agents in COVID-19 patients: systematic review and meta-analysis. *CMAJ* 2020. In press.

23. Yan D, Liu X-y, Zhu Y-n, et al. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection. *medRxiv* 2020 Mar. 30. doi: 10.1101/2020.03.22.20040832.

24. Zhou Q, Wei X-S, Xiang X, et al. Interferon-a2b treatment for COVID-19. *medRxiv* 2020 Apr. 10. doi: 10.1101/2020.04.06.20042580.

25. Chen C, Huang J, Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. *medRxiv* 2020 Apr. 15. doi: 10.1101/2020.03.17.20037432.

26. Cai QX, Yang MH, Liu DJ, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. *Engineering* 2020 Mar. 18 doi: 10.1016/j.eng.2020.03.007.

27. Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. *Pharmacotherapy* 2007;27:494-503.

28. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. *N Engl J Med* 2020 Mar. 18. doi: 10.1056/NEJMoa2001282. [Epub ahead of print].

29. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). *J Zhejiang Univ (Med Sci)* 2020 Mar. 6. doi: 10.3785/j.issn.1008-9292.2020.03.03.

30. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv* 2020 Apr. 10. doi: 10.1101/2020.03.22.20040758.

31. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. *medRxiv* 2020 Apr. 14 doi: 10.1101/2020.04.10.20060558.

32. Al Ghamdi M, Alghamdi KM, Ghandoora Y, et al. Treatment outcomes for patients with Middle Eastern respiratory syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. *BMC Infect Dis* 2016;16:174.

33. Leong HN, Ang B, Earnest A, et al. Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. *Trop Med Int Health* 2004;9:923-7.

34. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. *J Antimicrob Chemother* 2015;70:2129-32.

35. Liu Q, Fang X, Tian L, et al. The effect of arbidol hydrochloride on reducing mortality of COVID-19 patients: a retrospective study of real-world date from three hospitals in Wuhan. *medRxiv* 2020 Apr. 17. doi: 10.1101/2020.04.11.20056523.

36. Dose-finding study of favipiravir in the treatment of uncomplicated influenza. ClinicalTrials.gov: NCT01068912; 2010. Available: www.clinicaltrials.gov/show/NCT01068912 (accessed 2020 Mar. 28).

37. Mahevas M, Tran VT, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. *medRxiv* 2020 Apr. 14. doi: 10.1101/2020.04.10.20060699.

38. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. *medRxiv* 2020 Apr. 23. doi: 10.1101/2020.04.16.20065920.

39. Higgins JPT, Thomas J, editors. *Cochrane handbook for systematic reviews of interventions version 6.0*. Oxford (UK): The Cochrane Collaboration; updated July 2019.

40. Guyatt GH, Busse JW. Modification of Cochrane tool to assess risk of bias in randomized trials. Ottawa: Evidence Partners. Available: www.evidencepartners.com/resources/methodological-resources/ (accessed 2020 Apr. 26).

41. Busse JW, Guyatt GH. Tool to assess risk of bias in cohort studies. Ottawa: Evidence Partners. Available: www.evidencepartners.com/resources/methodological-resources/ (accessed 2020 Apr. 26).

42. Busse JW, Guyatt GH. Tool to assess risk of bias in case-control studies. Ottawa: Evidence Partners. Available: www.evidencepartners.com/resources/methodological-resources/ (accessed 2020 Apr. 26).

43. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011;64:401-6.

44. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. rating the quality of evidence — study limitations (risk of bias). *J Clin Epidemiol* 2011;64:407-15.

45. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. rating the quality of evidence — imprecision. *J Clin Epidemiol* 2011;64:1283-93.

46. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. rating the quality of evidence — inconsistency. *J Clin Epidemiol* 2011;64:1294-302.

47. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. rating the quality of evidence — indirectness. *J Clin Epidemiol* 2011;64:1303-10.

48. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. rating the quality of evidence — publication bias. *J Clin Epidemiol* 2011;64:1277-82.

49. Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9. rating up the quality of evidence. *J Clin Epidemiol* 2011;64:1311-6.

50. Schünemann HJ, Al-Ansary LA, Forland F, et al. Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines. *Ann Intern Med* 2015;163:548-53.

51. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Arlington (VA): Infectious Disease Society of America; 2020. Available: www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (accessed 2020 Apr. 26).

52. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). *Intensive Care Med* 2020 Mar. 28 [Epub ahead of print]. doi: 10.1007/s00134-020-06022-5.

53. COVID-19 guidelines version 1. Camberwell (AU): The Australian and New Zealand Intensive Care Society (ANZICS); 2020. Available: www.anzics.com.au/coronavirus-guidelines/ (accessed 2020 Apr. 26).

54. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community. London (UK): National Institute for Health and Care Excellence; 2020. Available: www.nice.org.uk/guidance/ng165 (accessed 2020 Apr. 26).

55. Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients. ISRCTN Registry. ISRCTN83971151; 2020. Available: www.isrctn.com/ISRCTN83971151 (accessed 2020 Apr. 26).

**Affiliations:** Department of Health Research Methods, Evidence and Impact Canada (Ye, Rochwerg, Guyatt, Colunga-Lozano) and of Medicine (Rochwerg), McMaster University, Hamilton, Ont.; Department of Pharmacy (Wang), Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; Department of Medicine, Interdepartmental Division of Critical Care Medicine (Adhikari, Fowler), University of Toronto, Toronto, Ont.; Department of Critical Care Medicine and Sunnybrook Research Institute (Adhikari, Fowler), Sunnybrook Health Sciences Centre, Toronto, Ont.; Department of Pediatrics (Murthy), University of British Columbia, Vancouver, BC; Department of Medicine (Lamontagne), Université de Sherbrooke; Centre de recherche du CHUS de Sherbrooke (Lamontagne), Sherbrooke, Que.; Department of Critical Care Medicine (Qiu), Zhongda hospital, School of Medicine, Southeast University, Nanjing, China; Department of Pharmacy (Wei), the First Affiliated Hospital of Guangzhou University of Medical; Department of Critical Care Medicine (Sang), the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou, China; Department of Pathology and Molecular Medicine and Health Research Methods, Evidence, and Impact (Loeb), McMaster University, Hamilton, Ont.; Department of Respiratory and Critical Care Medicine (Shen), Peking University Third Hospital, Beijing, China; Guangdong kuaiwen information technology co. LTD (Huang), Guanzhong, China; Kunshan Guanghui Precise Metal Co. Ltd. (Jiang), Kunshan, China; Intensive Care Department (Arabi), King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia; Department of Clinical Medicine (Colunga-Lozano), Health Science Center, Universidad de Guadalajara, Guadalajara, Mexico; Department of Critical Care Medicine (Jiang), Xuanwu Hospital, Capital Medical School, Beijing, China; Department of Pulmonary and Critical Care Medicine (Koh), University of Ulsan College of Medicine, Seoul, South Korea; Department of Pharmacy (Liu), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Department of Pharmacy (Liu, Zhai), Peking University Third Hospital, Beijing, China; Fast and Chronic Programmes (Phua), Alexandra Hospital, National University Health System, Singapore; Department of Pharmacy, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei (Shen), Anhui, China; General Surgery Department (Huo), Peking University Third Hospital, Beijing, China; Medical Intensive Care Unit (Du), Peking Union Medical College Hospital, Beijing